Target Points in Trastuzumab Resistance
Joint Authors
Rahimi Shamabadi, Abbas
Shojaei, Sahar
Gardaneh, Mossa
Source
International Journal of Breast Cancer
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-02-26
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation.
The human EGF2 (HER2) lacks natural ligands, and correlation between HER2 levels and carcinogenesis makes the receptor an ideal candidate for targeted therapy in breast cancer.
Trastuzumab is a humanized antibody applied against HER2-positive breast tumors in clinic.
Metastatic tumors respond well to trastuzumab therapy for the first year, but development of antibody resistance helps the tumors to regrow allowing the disease to progress.
Trastuzumab resistance is shaped via a range of intracellular signaling pathways that are interconnected and share in key effector molecules.
Identification of a common node central to these resistance pathways could provide an ultimate solution for trastuzumab resistance in breast and other cancers.
American Psychological Association (APA)
Shojaei, Sahar& Gardaneh, Mossa& Rahimi Shamabadi, Abbas. 2012. Target Points in Trastuzumab Resistance. International Journal of Breast Cancer،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-496746
Modern Language Association (MLA)
Shojaei, Sahar…[et al.]. Target Points in Trastuzumab Resistance. International Journal of Breast Cancer No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-496746
American Medical Association (AMA)
Shojaei, Sahar& Gardaneh, Mossa& Rahimi Shamabadi, Abbas. Target Points in Trastuzumab Resistance. International Journal of Breast Cancer. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-496746
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-496746